Aspira Women’s Health (AWH)
Search documents
Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO
GlobeNewswire News Room· 2024-12-16 13:45
AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira’s President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and externa ...
Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO
Newsfilter· 2024-12-16 13:45
AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external ...
Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award
GlobeNewswire News Room· 2024-12-03 13:00
AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (NASDAQ: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H’s Sprint for Women’s Health was created to ...
Aspira (AWH) Reports Q3 Loss, Lags Revenue Estimates
ZACKS· 2024-11-19 23:46
Aspira (AWH) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.48 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 17.86%. A quarter ago, it was expected that this diagnostic and bio-analytical company would post a loss of $0.32 per share when it actually produced a loss of $0.28, delivering a surprise of 12.50%.Over the last four quarters, the ...
Aspira Women’s Health (AWH) - 2024 Q3 - Quarterly Report
2024-11-19 21:35
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AWH The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ ...
Aspira Women’s Health (AWH) - 2024 Q3 - Earnings Call Transcript
2024-11-14 17:30
Aspira Women's Health Inc. (NASDAQ:AWH) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Nicole Sandford - Chief Executive Officer & Director Sandy Milligan - President John Kallassy - Interim Chief Financial Officer Conference Call Participants Operator Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared rem ...
Aspira Women’s Health (AWH) - 2024 Q3 - Quarterly Results
2024-11-14 13:02
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AWH The Nasdaq Stock Market FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 Aspira Women's Health Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-34810 33-0595156 (State or Other ...
AWH ANNOUNCES Q3 2024 FINANCIAL RESULTS
Prnewswire· 2024-11-12 12:00
Achieved $141.6 million Net Revenue in Q3 2024Reported $25.1 million in Adjusted EBITDAAnticipates $30 million of Annual Savings Through Transformation InitiativesMORRISTOWN, N.J., Nov. 12, 2024 /PRNewswire/ - Ascend Wellness Holdings, Inc. ("AWH," or the "Company" or "Ascend") (CSE: AAWH.U) (OTCQX: AAWH), a vertically integrated multi-state cannabis operator focused on bettering lives through cannabis, today reported its financial results for the three months ended September 30, 2024 ("Q3 2024"). Financial ...
Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024
GlobeNewswire News Room· 2024-11-04 13:00
AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Detai ...
Aspira Women's Health Issues Letter to Shareholders and Announces Virtual Research & Development Day on October 29, 2024
GlobeNewswire News Room· 2024-10-25 12:00
AUSTIN, Texas, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, has issued a letter to Company shareholders and announced it will host a virtual Research & Development Day on Tuesday, October 29, 2024, at 3:00 pm ET. The R&D Day will highlight the company’s plans for its miRNA development pipeline, including the recently announced award from the Advanced Res ...